# M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

> **NCT03517969** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 73 (actual)

## Conditions studied

- Castration-Resistant Prostate Carcinoma
- Metastatic Prostate Carcinoma
- Stage IV Prostate Cancer AJCC v8

## Interventions

- **DRUG:** Berzosertib
- **DRUG:** Carboplatin
- **DRUG:** Docetaxel
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT03517969
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-05-29
- **Primary completion:** 2021-08-10
- **Final completion:** 2027-04-03
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03517969

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03517969, "M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT03517969. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*